Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Pinnacle Bancorp Inc.

Pinnacle Bancorp Inc. boosted its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 52.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 190 shares of the medical research company’s stock after buying an additional 65 shares during the period. Pinnacle Bancorp Inc.’s holdings in Charles River Laboratories International were worth $35,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new stake in shares of Charles River Laboratories International in the 2nd quarter worth about $110,000. American Century Companies Inc. increased its stake in shares of Charles River Laboratories International by 4.6% in the second quarter. American Century Companies Inc. now owns 6,556 shares of the medical research company’s stock valued at $1,354,000 after purchasing an additional 291 shares during the period. DekaBank Deutsche Girozentrale increased its stake in shares of Charles River Laboratories International by 12.0% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,906 shares of the medical research company’s stock valued at $1,640,000 after purchasing an additional 850 shares during the period. Envestnet Asset Management Inc. raised its holdings in shares of Charles River Laboratories International by 3.7% during the second quarter. Envestnet Asset Management Inc. now owns 319,177 shares of the medical research company’s stock valued at $65,936,000 after buying an additional 11,514 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Charles River Laboratories International by 20.0% during the second quarter. Dimensional Fund Advisors LP now owns 561,075 shares of the medical research company’s stock worth $115,912,000 after buying an additional 93,682 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on CRL shares. UBS Group lifted their target price on Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Redburn Atlantic started coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 target price for the company. Bank of America dropped their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Finally, TD Cowen increased their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a report on Monday, November 11th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $214.00.

Charles River Laboratories International Stock Down 4.8 %

Shares of Charles River Laboratories International stock opened at $165.60 on Friday. Charles River Laboratories International, Inc. has a 12-month low of $160.85 and a 12-month high of $275.00. The firm has a market capitalization of $8.47 billion, a PE ratio of 20.73, a price-to-earnings-growth ratio of 6.62 and a beta of 1.38. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The stock’s fifty day moving average is $192.56 and its 200-day moving average is $198.95.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same quarter in the previous year, the company earned $2.72 EPS. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).